A successful management with electroconvulsive therapy of neuroleptic malignant syndrome due to amisulpride
More details
Hide details
Department of Child and Adolescent Psychiatry, Gaziantep Child State Hospital, Gaziantep, Turkey
Department of Psychiatry, Gaziantep University, Faculty of Medicine, Gaziantep, Turkey
Erenköy Training and Research Hospital for Psychiatric and Neurological Diseases, Department of Psychiatry, İstanbul, Turkey
Department of Psychiatry, Hitit University, Faculty of Medicine, Çorum, Turkey
Submission date: 2018-01-14
Acceptance date: 2018-01-19
Online publication date: 2018-02-14
Publication date: 2018-02-13
Electron J Gen Med 2018;15(3):em14
Neuroleptic malignant syndrome is a severe complication that mainly occurs based on neuroleptic drug treatment and characterized with some autonomic symptoms, altered mental state, hyperthermia and muscle rigidity. Amisulpride is a unique atypical antipsychotic that selectively blocks D2 and D3 receptors presynaptically in the frontal cortex and atypical antipsychotics are rarely caused neuroleptic malignant syndrome(NMS).This study examine a 20-years old male with the diagnosis of acute psychotic disorder occurred amisulpride-induced NMS and successfully treated with Electroconvulsive Therapy (ECT). We decided to present that case because of the fact that there is only limited number of amisulpride-induced NMS cases reported in the literature.
Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. The American journal of psychiatry. 1998;155(8):1113-6. PubMed PMID: 9699705. Epub 1998/08/12.
Levenson JL. Neuroleptic malignant syndrome. The American journal of psychiatry. 1985;142(10):1137-45. PubMed PMID: 2863986. Epub 1985/10/01.
Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. The American journal of psychiatry. 2002;159(1):149-50. PubMed PMID: 11772710. Epub 2002/01/05.
Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2004;28(1):89-98. PubMed PMID: 14687862. Epub 2003/12/23.
Khaldi S, Kornreich C, Choubani Z, Gourevitch R. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]. L'Encephale. 2008;34(6):618-24. PubMed PMID: 19081460. Epub 2008/12/17. Antipsychotiques atypiques et syndrome malin des neuroleptiques: breve revue de la litterature.
Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. The Journal of pharmacology and experimental therapeutics. 1997;280(1):83-97. PubMed PMID: 8996185. Epub 1997/01/01.
Shoirah H, Hamoda HM. Electroconvulsive therapy in children and adolescents. Expert review of neurotherapeutics. 2011;11(1):127-37. PubMed PMID: 21158560. Epub 2010/12/17.
Rey JM, Walter G. Half a century of ECT use in young people. The American journal of psychiatry. 1997;154(5):595-602. PubMed PMID: 9137112. Epub 1997/05/01.
Guy W. Early clinical drug evaluation unit (ECDEU) asssment manual psychopharmology. Revised. Rockville, National Institude of Mental Health US.1976;76:217-22.
Kostakoğlu E, Batur S, Tiryaki A, Göğüş A. Pozitif ve Negatif Sendrom Ölçeğinin (PANSS) Türkçe uyarlamasının Geçerlilik ve Güvenilirliği. Türk Psikoloji Dergisi. 1999;14:23-32.
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Current neuropharmacology. 2015;13(3):395-406. PubMed PMID: 26411967. PMCID: 4812801. Epub 2015/09/29.
de Oliveira IR, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. Journal of clinical pharmacy and therapeutics. 1996;21(5):349-58. PubMed PMID: 9119918. Epub 1996/10/01.
Mandal N, Singh OP, Sen S. Extrapyramidal side effects with low doses of amisulpride. Indian journal of psychiatry. 2014;56(2):197-9. PubMed PMID: 24891713. PMCID: 4040073. Epub 2014/06/04.
Tu MC, Hsiao CC. Amisulpride and neuroleptic malignant syndrome. Chang Gung medical journal. 2011;34(5):536-40. PubMed PMID: 22035899. Epub 2011/11/01.
Musshoff F, Doberentz E, Madea B. Lethal neuroleptic malignant syndrome due to amisulpride. Forensic science, medicine, and pathology. 2013;9(2):218-20. PubMed PMID: 23504701. Epub 2013/03/19.
Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs in R&D. 2015;15(1):45-62. PubMed PMID: 25578944. PMCID: 4359181. Epub 2015/01/13.
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. British journal of anaesthesia. 2000;85(1):129-35. PubMed PMID: 10928001. Epub 2000/08/06.
Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. Journal of neurology, neurosurgery, and psychiatry. 1995;58(3):271-3. PubMed PMID: 7897404. PMCID: 1073359. Epub 1995/03/01.
Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y. Malignant neuroleptic syndrome--its present status in Japan and clinical problems. Folia psychiatrica et neurologica japonica. 1977;31(4):559-76. PubMed PMID: 608659. Epub 1977/01/01.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981;30(2):239-45. PubMed PMID: 7249508. Epub 1981/08/01.
Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. The Australian and New Zealand journal of psychiatry. 1999;33(5):650-9. PubMed PMID: 10544988. Epub 1999/11/02.
Casey DA. Electroconvulsive Therapy in the Neuroleptic Malignant Syndrome. Convulsive therapy. 1987;3(4):278-83. PubMed PMID: 11940929. Epub 1987/01/01.
Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta psychiatrica Scandinavica. 1986;73(4):337-47. PubMed PMID: 2873715. Epub 1986/04/01.
Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists. 2012;24(2):155-62. PubMed PMID: 22563571. Epub 2012/05/09.
Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacology bulletin. 1991;27(3):381-4. PubMed PMID: 1685592. Epub 1991/01/01.
Journals System - logo
Scroll to top